Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Whitehawk Therapeutics Inc (WHWK)

Whitehawk Therapeutics Inc (WHWK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Whitehawk Therapeutics Advances to Clinical Stage with IND Clearance for HWK-007 and Announces IND Submission for HWK-016 PR Newswire - Thu Jan 8, 7:00AM CST

Actively recruiting Phase 1 trial for PTK7-targeted antibody-drug conjugate (ADC) HWK-007

WHWK : 2.71 (-6.55%)
Whitehawk Therapeutics Appoints Margaret Dugan, MD, as Chief Medical Officer PR Newswire - Mon Dec 1, 2025

Dr. Dugan brings extensive clinical development leadership to Whitehawk as ADC programs near the clinic

WHWK : 2.71 (-6.55%)
Whitehawk Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference PR Newswire - Wed Nov 26, 2025

MORRISTOWN, N.J. , Nov. 26, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently...

WHWK : 2.71 (-6.55%)
AI-Powered Platforms Scale as Preventive Care and Biomarker Testing Converge BayStreet.ca - Tue Nov 18, 2025

VANCOUVER – Baystreet.ca News Commentary – Healthcare providers are prioritizing preventive care strategies as nearly 58% now integrate biomarker testing into early wellness indicators [1], a shift...

HIMS : 23.48 (-3.77%)
TEM : 52.44 (-2.07%)
WHWK : 2.71 (-6.55%)
BFLY : 3.23 (-11.99%)
ALEN-U.CN : 1.3500 (-8.16%)
Whitehawk Therapeutics to Present at Jefferies Global Healthcare Conference in London PR Newswire - Tue Nov 11, 2025

MORRISTOWN, N.J. , Nov. 11, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently...

WHWK : 2.71 (-6.55%)
Whitehawk Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights PR Newswire - Thu Nov 6, 2025

MORRISTOWN, N.J. , Nov. 6, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently...

WHWK : 2.71 (-6.55%)
Funding Is Back in Digital Health, Marking Move into AI Wellness Renaissance BayStreet.ca - Tue Nov 4, 2025

Issued on behalf of Aleen Inc. VANCOUVER – Baystreet.ca News Commentary – So far, the latest Q3 funding surge[1] has shown digital wellness building speed again as investors are backing AI...

CCLD : 2.25 (-7.79%)
TEM : 52.44 (-2.07%)
WHWK : 2.71 (-6.55%)
WAY : 24.13 (+0.58%)
ALEN-U.CN : 1.3500 (-8.16%)
Whitehawk Therapeutics Presents Real-World Analysis Confirming PTK7 as a Broadly Expressed, Clinically Relevant Target Across Solid Tumors at AACR-NCI-EORTC PR Newswire - Fri Oct 24, 2025

PTK7 is the third most highly expressed tumor marker among clinically validated and emerging ADC targets, present in ~70% of tumors

WHWK : 2.71 (-6.55%)
Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research Business Wire - Thu Oct 16, 2025

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a multi-year collaboration with Whitehawk Therapeutics, Inc. (NASDAQ: WHWK),...

TEM : 52.44 (-2.07%)
WHWK : 2.71 (-6.55%)
Whitehawk Therapeutics to Participate in Upcoming Investor Conferences PR Newswire - Tue Sep 2, 2025

MORRISTOWN, N.J. , Sept. 2, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology...

WHWK : 2.71 (-6.55%)

Barchart Exclusives

1 Dividend Stock to Buy Now as Trump Tackles Housing Affordability Barchart - Thu Feb 5, 6:30PM CST
Trump’s push to lower mortgage rates, cap card interest, and curb institutional home buying puts dividend‑payer Lennar at the center of the housing‑affordability trade, with the stock still trading at a modest discount. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot